Evidence map›Paper›PMID 30425966›Full record

ArticleFrontiers in oncology2018

Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the

Athar Khalil, Batoul Dekmak, Fouad Boulos, Jake Kantrowitz, Avrum Spira, Junya Fujimoto, Humam Kadara, Nehme El-Hachem, Georges Nemer

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Genes & diseases · 2026
    Article
  2. Article
  3. Article
  4. Identification ofPeerJ · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Epigenetic Suppression of the T-box Subfamily 2 (International journal of molecular sciences · 2019
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Athar KhalilDepartments of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Batoul DekmakDepartments of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Fouad BoulosDepartment of Pathology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Jake KantrowitzSection of Computational Biomedicine, Boston University, Boston, MA, United States.
Avrum SpiraSection of Computational Biomedicine, Boston University, Boston, MA, United States.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Humam KadaraDepartments of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Nehme El-HachemFaculty of Medicine and Genome Innovation Centre, McGill University, Montreal, QC, Canada.
Georges NemerDepartments of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
American University of Beirut · LBBoston University · USThe University of Texas MD Anderson Cancer Center · USMcGill University and Génome Québec Innovation Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-box (TBX) transcription factors are evolutionary conserved genes and master transcriptional regulators. In mammals, TBX2 subfamily (TBX2, TBX3, TBX4, and TBX5) genes are expressed in the developing lung bud and tracheae. Our group previously showed that the expression of TBX2 subfamily was significantly high in human normal lungs, but markedly suppressed in lung adenocarcinoma (LUAD). To further elucidate their role in LUAD pathogenesis, we first confirmed abundant expression of protein products of the four members by immunostaining in adult human normal lung tissues. We also found overall suppressed expression of these genes and their corresponding proteins in a panel of human LUAD cell lines. Transient over-expression of each of the genes in human (NCI-H1299), and mouse (MDA-F471) derived lung cancer cells was found to significantly inhibit growth and proliferation as well as induce apoptosis. Genome-wide transcriptomic analyses on NCI-H1299 cells, overexpressing TBX2 gene subfamily, unraveled novel regulatory pathways. These included, among others, inhibition of cell cycle progression but more importantly activation of the histone demethylase pathway. When using a pattern-matching algorithm, we showed that TBX's overexpression mimic molecular signatures from azacitidine treated NCI-H1299 cells which in turn are inversely correlated to expression profiles of both human and murine lung tumors relative to matched normal lung. In conclusion, we showed that the TBX2 subfamily genes play a critical tumor suppressor role in lung cancer pathogenesis through regulating its methylating pattern, making them putative candidates for epigenetic therapy in LUAD.

Indexed as

demethylationlung adenocarcinomaT-Boxtranscriptomicstumor suppressor gene

Identifiers

PMID30425966
PMCPMC6218583
OpenAlexW2898642188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.